The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Special Sections: Letters to the Editor

Paclitaxel: Friend or Foe for Systemic Lupus Erythematosus?

Authors: Hai-Feng Pan MD, Guo-Cui Wu MM, Xiang-Pei Li MD, Dong-Qing Ye MD

Abstract

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. Dasanu CA, Alexandrescu DT. Systemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer. South Med J 2008;101:1161–1162.DasanuCA]]AlexandrescuDTSystemic lupus erythematosus associated with paclitaxel use in the treatment of ovarian cancer.South Med J20081011161-11622. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol 2004;29:360–362.FarrantPB]]MortimerPS]]GoreMScleroderma and the taxanes. Is there really a link?Clin Exp Dermatol200429360-3623. Kupfer I, Balguerie X, Courville P, et al. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol 2003;48:279–281.KupferI]]BalguerieX]]CourvilleP&etal;Scleroderma-like cutaneous lesions induced by paclitaxel: a case study.J Am Acad Dermatol200348279-2814. Lortholary A, Cary-Ten Have Dallinga M, El Kouri C, et al. [Paclitaxelinduced lupus]. Presse Med 2007;36:1207–1208 [in French].5. Adachi A, Horikawa T. Paclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody. J Dermatol 2007; 34:473–476.AdachiA]]HorikawaTPaclitaxel-induced cutaneous lupus erythematosus in patients with serum anti-SSA/Ro antibody.J Dermatol200734473-4766. Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int Immunopharmacol 2003;3:1699–1714.FitzpatrickFA]]WheelerRThe immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents.Int Immunopharmacol200331699-17147. Song YW, Kim HA, Baek HJ, et al. Paclitaxel reduces anti-dsDNA antibody titer and BUN, prolonging survival in murine lupus. Int J Immunopharmacol 1998;20:669–677.SongYW]]KimHA]]BaekHJ&etal;Paclitaxel reduces anti-dsDNA antibody titer and BUN, prolonging survival in murine lupus.Int J Immunopharmacol199820669-677